Effects of genetic polymorphisms on the pharmacokinetics and pharmacodynamics of proton pump inhibitors

• Published in: Pharmacological research Vol. 152; p. 104606
• Main Authors: Zhang, He-Jian, Zhang, Xue-Hui, Liu, Jie, Sun, Lu-Ning, Shen, Yi-Wen, Zhou, Chen, Zhang, Hong-Wen, Xie, Li-Jun, Chen, Juan, Liu, Yun, Wang, Yong-Qing
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 01.02.2020
• Subjects: 2-Pyridinylmethylsulfinylbenzimidazoles - pharmacokinetics; 2-Pyridinylmethylsulfinylbenzimidazoles - pharmacology; CYP2C19; Gastric H+K+-ATPase; Humans; Pharmacodynamics; Pharmacogenomic Variants; Pharmacokinetics; Polymorphism; Proton pump inhibitors (PPIs); Proton Pump Inhibitors - pharmacokinetics; Proton Pump Inhibitors - pharmacology; homEMs; Dexlansoprazole (PubChem CID: 9578005); Esomeprazole (PubChem CID: 9568614); H. pylori; CYP2C19; AUC; CYP450; t1/2; PMs; SNPs; Lansoprazole (PubChem CID: 3883); UMs; Omeprazole (PubChem CID: 4594); Rabeprazole (PubChem CID: 5029); Gastric H+K+-ATPase; Cmax; Pharmacodynamics; MR; hetEMs; PPIs; Proton pump inhibitors (PPIs); Ilaprazole (PubChem CID: 214351); H+,K+-ATPase; PD; H2RAs; Pantoprazole (PubChem CID: 4679); PK; Pharmacokinetics; TpH>4 (%); Polymorphism; Gastric H(+)K(+)-ATPase

[Display omitted] Proton pump inhibitors (PPIs) are used widely for the treatment of acid-related disorders. Despite their excellent efficacy and tolerance, the pharmacodynamics and pharmacokinetics of PPIs are affected by each patient’s CYP2C19 and gastric H+,K+-ATPase genotype. The aim of this rev...